APA (7th ed.) Citation

Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J., . . . Hayashi, H. (2024). Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. The New England journal of medicine, 391(16), . https://doi.org/10.1056/NEJMoa2403614

Chicago Style (17th ed.) Citation

Cho, Byoung C., et al. "Amivantamab Plus Lazertinib in Previously Untreated EGFR-mutated Advanced NSCLC." The New England Journal of Medicine 391, no. 16 (2024). https://doi.org/10.1056/NEJMoa2403614.

MLA (9th ed.) Citation

Cho, Byoung C., et al. "Amivantamab Plus Lazertinib in Previously Untreated EGFR-mutated Advanced NSCLC." The New England Journal of Medicine, vol. 391, no. 16, 2024, https://doi.org/10.1056/NEJMoa2403614.